BookMathias Schwanstecher, editor.
Contents:
Targeting type 2 diabetes
Dual acting and pan-PPAR activators as potential anti-diabetic therapies
GLP-1 agonists and dipeptidyl-peptidase IV inhibitors
Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes
SGLT inhibitors as new therapeutic tools in the treatment of diabetes
Inhibitors of 11[beta]-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy
Nampt and its potential role in inflammation and type 2 diabetes
Inhibition of ganglioside biosynthesis as a novel therapeutic approach in insulin resistance
Overcoming insulin resistance with ciliary neurotrophic factor
Thermogenesis and related metabolic targets in anti-diabetic therapy
Interleukin-targeted therapy for metabolic syndrome and type 2 diabetes
Fructose-1, 6-bisphosphatase inhibitors for reducing excessive endogenous glucose production in type 2 diabetes
AMP-activated protein kinase and metabolic control
Mitochondria as potential targets in antidiabetic therapy
Research and development of glucokinase activators for diabetes therapy : theoretical and practical aspects.